Adagrasib + Olaparib for Solid Tumors
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing a combination of two drugs, adagrasib and olaparib, in patients with advanced solid tumors that have specific genetic mutations. The goal is to find a safe dose and see if the combination can effectively block cancer growth and prevent cancer cells from repairing themselves. Olaparib has shown activity in various cancers, particularly those with certain genetic mutations.
Will I have to stop taking my current medications?
The trial requires a 2-week washout period (time without taking certain medications) for strong or moderate CYP3A inhibitors and a 5-week washout period for strong or moderate CYP3A inducers before starting the study treatment. If you are taking medications that fall into these categories, you may need to stop or switch them before participating.
What safety data exists for Adagrasib + Olaparib in humans?
What makes the drug combination of Adagrasib and Olaparib unique for treating solid tumors?
The combination of Adagrasib and Olaparib is unique because it targets solid tumors by combining two different mechanisms: Adagrasib targets specific cancer mutations, while Olaparib inhibits enzymes (PARP-1 and PARP-2) that help repair DNA damage in cancer cells, potentially enhancing the treatment's effectiveness.35678
What data supports the effectiveness of the drug Olaparib in treating solid tumors?
Olaparib has shown effectiveness in treating ovarian cancer, particularly in patients with BRCA mutations, by targeting cancer cells' DNA repair mechanisms. It is approved for use in ovarian cancer and has been studied for its potential benefits in other cancers with similar DNA repair issues.368910
Who Is on the Research Team?
Timothy Yap
Principal Investigator
M.D. Anderson Cancer Center
Are You a Good Fit for This Trial?
Adults with advanced solid tumors that have specific mutations (KRAS G12C or KEAP1) can join this trial. They should be in good physical condition, not have major health issues that could affect the study, and agree to use effective contraception. People with certain gastrointestinal conditions, uncontrolled infections, recent significant bleeding or surgery, or those on strong CYP3A inhibitors/inducers are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive adagrasib and olaparib by mouth twice daily to evaluate safety, tolerability, and establish the recommended dose
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Adagrasib
- Olaparib
Adagrasib is already approved in United States, European Union for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
M.D. Anderson Cancer Center
Lead Sponsor
Mirati Therapeutics Inc.
Industry Sponsor
Dr. Charles M. Baum
Mirati Therapeutics Inc.
Chief Executive Officer since 2023
MD, PhD
Dr. Joseph Leveque
Mirati Therapeutics Inc.
Chief Medical Officer since 2021
MD